RPG Life Sciences

RPG Life Sciences delivered a strong Q4 FY26 with revenue of 176.9 crCurrent reported value: 176.9 cr. No comparable prior figure is available in the source record. (+23.6Current reported value: 23.6. No comparable prior figure is available in the source record.% YoY) and EBITDA of 45.2 crCurrent reported value: 45.2 cr. No comparable prior figure is available in the source record. (+48% YoY), driven by domestic formulation growth of 18.2%Current 18.2%. Reported change: +8.1pp YoY. (1.8x IPM) and a sharp recovery in API (Q4 revenue 33.3 crCurrent 33.3 cr. Reported change: +144% QoQ.). The domestic business outpaced the market on volume growth (9% vs 1.1%), while new introductions contributed 5.1%. Management guided for sustained mid-teens domestic growth, API as a growth driver with a pipeline of 13 molecules, and international formulation returning to growth post inventory normalization. Key risks include potential raw material cost inflation from geopolitical tensions and regulatory delays in export markets.